Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
420
Not yet recruiting, industry sponsors, Oncology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting2,031
- Completed5,416
420 trials
Showing 1 to 25, recently updated first.
- A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid TumorsNot yet recruiting
BioNTech SEIndustry
NCT07951359 · 345 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: BNT3211 · For: Advanced Solid Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07951762 · 368 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2028
Drug: SYS6043+PD-1/VEGF bispecific antibody; SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy. and 1 more · For: Advanced Solid Tumor
Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
NCT07765524 · 32 participants (planned) · Start Dec 2026 · Primary completion Mar 2028
Drug: FKC289 infusion · For: Primary Light Chain (AL) Amyloidosis
Sites: Guangzhou, China; Nanning, China; Zhengzhou, China · 11 sites in all
- DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.Not yet recruiting
Audax Biosciences Pty. Ltd.Industry
NCT07950930 · 142 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 10, 2030
Drug: DAX-044 · For: Advanced Solid Tumours
Sites: Nedlands, Australia
- YSCH-01 for Recurrent or Progressive GlioblastomaNot yet recruiting
Shanghai Yuansong Biotechnology Co., Ltd.Industry
NCT07948109 · 32 participants (planned) · Start Nov 10, 2026 · Primary completion Dec 2028
Drug: YSCH-01 · For: Recurrent Glioblastoma (WHO-Grade IV Glioma); Progressive Glioblastoma; Recurrent Glioblastoma
Sites: Shanghai, China
- A Study of HLX105 in Patients With Advanced or Metastatic Solid TumorsNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07949669 · 42 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2027
Drug: HLX105 · For: Solid Tumor (Phase I)
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid TumorsPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07944690 · 222 participants (planned) · Start Nov 2026 · Primary completion Dec 2029
Drug: HLX49; Trastuzumab Deruxtecan for Injection (T-DXd) · For: Advanced/Metastatic Solid Tumors
Sites: Sunshine Coast, Australia; Beijing, China
- A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947134 · 155 participants (planned) · Start Nov 25, 2026 · Primary completion Nov 16, 2029
Drug: GSK5864399 · For: Solid Tumours
- A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid TumorsPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07944144 · 205 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 28, 2030
Drug: IPN60350 · For: Neoplasms; Neoplasm Metastasis; Neoplastic Processes and 1 more
- Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid TumorsNot yet recruiting
Frontier Medicines CorporationIndustry
NCT07944092 · 282 participants (planned) · Start Dec 2026 · Primary completion Jan 2029
Drug: FMC-242; Trastuzumab (or biosimilar) and 3 more · For: Locally Advanced Solid Tumor
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruiting
PfizerPfizer (PFE)
NCT07897721 · 268 participants (planned) · Start Nov 9, 2026 · Primary completion Mar 22, 2030
Drug: PF-08165784; Fulvestrant and 3 more · For: Advanced Breast Cancer; Advanced or Metastatic Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-) and 1 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 5 sites in all
- A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid TumorsNot yet recruiting
CStone PharmaceuticalsIndustry
NCT07938814 · 310 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: CS5006 · For: Advanced Solid Tumors
Sites: North Ryde, Australia; Randwick, Australia; Clayton, Australia · 4 sites in all
- A Study of BON-C1393 in Adults With Advanced Solid TumorsNot yet recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07904845 · 90 participants (planned) · Start Nov 23, 2026 · Primary completion Feb 27, 2029
Drug: BON-C1393; Bevacizumab and 1 more · For: Solid Tumors; Advanced Solid Tumors
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07943078 · 200 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 5, 2029
Drug: JNJ-99220732 · For: Neoplasms
- Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of ResponseNot yet recruiting
NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)Industry
NCT07767110 · 20 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Drug: LSAM-Cisplatin · For: Diffuse Midline Glioma (DMG); Diffuse Intrinsic Pontine Glioma (DIPG); Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
- 177Lu-ACT319 in FAP Expressing Solid TumorsNot yet recruiting
Actithera INC.Industry
NCT07941362 · 182 participants (planned) · Start Oct 25, 2026 · Primary completion Jul 31, 2029
Drug: 177Lu-ACT319; 177Lu-ACT319 and 6 more · For: FAP-expressing Solid Tumors; Pancreatic Ductal Adenocarcinoma (PDAC); Biliary Tract Carcinoma (BTC)
- A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07939815 · 171 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 29, 2029
Drug: BMS-986548; Cetuximab · For: Advanced Solid Malignancies
Sites: San Antonio, Texas; West Valley City, Utah; Vancouver, Canada · 4 sites in all
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07940439 · 126 participants (planned) · Start Nov 2026 · Primary completion Dec 2030
Drug: HRS-9308 Tablet · For: Solid Tumor
Sites: Shanghai, China
- S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c MutationNot yet recruiting
ServierIndustry
NCT07722312 · 80 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 11, 2029
Drug: S243249 600mg; S243249 400mg and 2 more · For: Relapsed or Refractory Acute Leukemia; Relapsed or Refractory Acute Myeloid Leukemia
- A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLNot yet recruiting
TuHURA Biosciences, Inc.Industry
NCT07939971 · 55 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: TBS-2025 · For: Acute Myeloid Leukemia
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07870278 · 80 participants (planned) · Start Nov 13, 2026 · Primary completion Jul 5, 2031
Drug: MK-6255; Acetaminophen and 5 more · For: Ovarian Neoplasms; Endometrial Neoplasms
Sites: East Brunswick, New Jersey
- A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and PharmacokineticsNot yet recruiting
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07940166 · 175 participants (planned) · Start Nov 2026 · Primary completion Jan 2029
Drug: HRS-8046 Tablet · For: Solid Tumor
Sites: Nanjing, China; Shanghai, China
- A Study of AK158D1 in Advanced Solid TumorsNot yet recruiting
AkesoIndustry
NCT07939919 · 349 participants (planned) · Start Nov 16, 2026 · Primary completion Apr 30, 2028
Drug: AK158D1 · For: Solid Malignant Tumor
Sites: Beijing, China; Guangzhou, China
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07933419 · 558 participants (planned) · Start Nov 15, 2026 · Primary completion Nov 15, 2027
Drug: QLS5133; Lenvatinib mesylate; QLS5133; QL2107; Lenvatinib mesylate and 4 more · For: Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Other Advanced Solid Tumors
Sites: Jinan, China
- First Study Evaluating the Safety and Dosage of YG-01 in Patients With GlioblastomaNot yet recruiting
YGION Biomedical GmbHIndustry
NCT07930338 · 15 participants (planned) · Start Nov 2026 · Primary completion Apr 2028
Drug: YG-01 Dose Level 1; YG-01 Dose Level 2 · For: Glioblastoma
Sites: Vienna, Austria
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.